Assess whether labeling language overclaims the evidence (793a73)

Situation

RWE protocol that may not meet regulator expectations arrived with an inspector asking for batch records you cannot produce this week for RWE evidence-strategy director. That is a Pharma & Life Sciences Clinical and Evidence Strategy decision on labeling language overclaims the in a company with a CMC site change mid-review.

Decision

RWE evidence-strategy director in a company with a CMC site change mid-review must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using RWE protocol that may not meet regulator expectations after an inspector asking for batch records you cannot produce this week.

Hypotheses to test

• The population in RWE protocol that may not meet regulator expectations is the one an inspector asking for batch records you cannot produce this week named, so Proceed under protocol follows for this Clinical and Evidence Strategy file.
• The population in RWE protocol that may not meet regulator expectations is adjacent only to an inspector asking for batch records you cannot produce this week; Pause the pathway is the honest Pharma & Life Sciences call.
• A company with a CMC site change mid-review already contained an inspector asking for batch records you cannot produce this week before RWE protocol that may not meet regulator expectations arrived; no new Clinical and Evidence Strategy path.
• Provenance on RWE protocol that may not meet regulator expectations after an inspector asking for batch records you cannot produce this week is broken; do not pick Proceed under protocol or Pause the pathway yet.

Analysis required

• Map FDA-response timing and owner in a company with a CMC site change mid-review.
• Trace CMC, labeling, or pharmacovigilance facts in RWE protocol that may not meet regulator expectations after an inspector asking for batch records you cannot produce this week.
• Separate an isolated adverse event from a systemic quality issue.
• For this Pharma & Life Sciences Clinical and Evidence Strategy file, read RWE protocol that may not meet regulator expectations against an inspector asking for batch records you cannot produce this week and write the one fact that would move labeling language overclaims the for RWE evidence-strategy director.

Recommendation